Annual General Meeting of Kuros Biosciences approves all resolutions
Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today…
Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today…
Omnipräsent und immer im Austausch: Am 11. April zieht es Ibexa nach Köln. Gemeinsam mit platform.sh bilden Ibexa und de…
Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it wi…
Direct MagnetOs sales grew to CHF 20.4 million in the first nine months of 2023, climbing from CHF 8.1 million in th…
. Financial Highlights Direct MagnetOs sales increased by 148% from CHF 4.9 million to CHF 12.2 million, total revenue…
First investigational trial of drug-biologic bone graft for spinal fusion 50 patients have been enrolled in the Phase 2…
Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today…
Direct MagnetOs sales climbed from CHF 2.0 million in Q1 2022 to CHF 5.4 million in Q1 2023. Total medical device sales…
. Financial highlights Direct sales of MagnetOs rose 75% from CHF 6.9 million to CHF 12.1 million in 2022. Total reven…
Publications in peer reviewed Journal of Immunology and Regenerative Medicine and Clinical Oral Implants Research Adds…